FDA outlines criteria for conducting long-term neurodevelopmental safety studies in neonates
FDA offers guidance on long-term neonate product studies: The FDA released draft guidance outlining recommendations for sponsors when conducting long-term neurodevelopmental studies to support the safety of medical products such as drugs, biologics or devices intended for use in neonates. According to the guidance, “although a single-arm study may be useful for collecting some types of safety information, the absence of a concurrent control arm (placebo or active comparator) will generally make clear interpretation of the results difficult, if not impossible.”